MYRIAD GENETICS INC (MYGN)
US62855J1043 - Common Stock
ChartMill assigns a Buy % Consensus number of 71% to MYGN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 23.6. This target is 74.78% above the current price.
MYGN was analyzed by 21 analysts. The buy percentage consensus is at 71. So analysts seem to be have mildly positive about MYGN.
In the previous month the buy percentage consensus was at a similar level.
MYGN was analyzed by 21 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-12-13 | B of A Securities | Maintains | Underperform -> Underperform |
| 2024-12-10 | UBS | Initiate | Neutral |
| 2024-12-09 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-11-18 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-11-11 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-09-19 | Morgan Stanley | Initiate | Equal-Weight |
| 2024-08-27 | Wells Fargo | Initiate | Overweight |
| 2024-08-13 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-08-13 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-08-07 | TD Cowen | Maintains | Hold -> Hold |
| 2024-08-07 | JP Morgan | Maintains | Underweight -> Underweight |
| 2024-06-27 | ScotiaBank | Initiate | Sector Outperform |
| 2024-05-13 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-05-08 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2024-01-30 | Goldman Sachs | Maintains | Buy -> Buy |
| 2024-01-29 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-12-21 | Piper Sandler | Initiate | Neutral |
| 2023-12-19 | Wells Fargo | Initiate | Equal-Weight |
| 2023-12-14 | Guggenheim | Initiate | Buy |
| 2023-12-13 | Wolfe Research | Initiate | Outperform |
| 2023-11-07 | JP Morgan | Maintains | Underweight -> Underweight |
| 2023-08-07 | JP Morgan | Maintains | Underweight -> Underweight |
| 2023-07-24 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-07-21 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-05-24 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-05-23 | Goldman Sachs | Upgrade | Sell -> Buy |
| 2023-05-04 | Stephens & Co. | Reiterate | Equal-Weight |
| 2023-05-04 | Goldman Sachs | Maintains | Sell |
| 2023-03-06 | Stephens & Co. | Maintains | Equal-Weight |
| 2023-03-03 | Raymond James | Maintains | Outperform |